Tolerability of induction chemotherapy dosing practices in acute myeloid leukemia patients

Highlights • We assess dose capping in patients receiving induction chemotherapy for acute myeloid leukemia. • Dose capping did not impact toxicity rates in those with a BSA > 2 compared to those with a BSA < 2. • Delivery of unadjusted chemotherapy for those with a BSA > 2 is likely safe i...

Full description

Saved in:
Bibliographic Details
Published inLeukemia research Vol. 39; no. 2; pp. 173 - 176
Main Authors Peric, Kaylene M, Reeves, David J
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.02.2015
Subjects
Acute myeloid leukemia
Bacteremia - chemically induced
Bacteremia - epidemiology
Body Surface Area
Dosing
Febrile Neutropenia - chemically induced
Febrile Neutropenia - epidemiology
Female
Hematology, Oncology and Palliative Medicine
Humans
Incidence
Induction Chemotherapy
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - epidemiology
Male
Middle Aged
Mucositis - chemically induced
Mucositis - epidemiology
Nausea - chemically induced
Nausea - epidemiology
Obesity
Retrospective Studies
Vomiting - chemically induced
Vomiting - epidemiology
Dosing
Obesity
Acute myeloid leukemia
Online AccessGet full text

Cover

More Information
Summary:Highlights • We assess dose capping in patients receiving induction chemotherapy for acute myeloid leukemia. • Dose capping did not impact toxicity rates in those with a BSA > 2 compared to those with a BSA < 2. • Delivery of unadjusted chemotherapy for those with a BSA > 2 is likely safe in hematologic malignancies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2014.11.024